When solutions exist, suffering shouldn't. 

We’re on a mission to restore comfort, dignity, and hope to breast cancer patients who have inoperable local recurrence and are left behind by today’s treatment options.

Wiradia is investigating the potential to introduce a water-filtered Infrared-A (wIRA®) hyperthermic radiosensitizer to the US, which would make re-irradiation a viable treatment option for patients who would otherwise be ineligible.

In European clinical practice, leading university cancer hospitals use wIRA with low-dose re-irradiation to support meaningful tumor control while helping reduce treatment-related toxicity in heavily pre-treated patients.

In the US, Wiradia’s device is investigational and limited by US law to investigational use. It is not available for commercial distribution in the US.

Wiradia LLC is a partner of Heckel Medizintechnik GmbH and Hydrosun Medizintechnik GmbH.

Wiradia

Org chart

Teams

Offices

Wiradia

Org chart

Teams

Offices

Related companies